Drug Profile
CDX 2401
Alternative Names: CDX-2401; DCVax-001; HIV vaccine - Celldex Therapeutics Inc/Rockefeller UniversityLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Celldex Therapeutics Inc
- Developer Celldex Therapeutics Inc; Rockefeller University
- Class AIDS vaccines; Monoclonal antibodies; Recombinant fusion proteins
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 15 Feb 2012 Phase-I development is ongoing in USA
- 26 May 2010 Phase-I clinical trials in HIV infections in USA (SC)
- 13 Feb 2009 Preclinical development is ongoing in USA